The global tumor necrosis factor (TNF) inhibitor drugs market is projected to exhibit moderate growth through the forecast period, driven by the emergence of biosimilars and rising incidence of autoimmune diseases. The therapeutic landscape faces intense competitive rivalry – both internally and externally.
TNF is a cytokine activator for multiple pathways, including MAPK and NFkB pathway, leading to a production cascade of other cytokines as well as TNF-induced apoptosis. Excess TNF is blocked in healthy individuals, but rheumatically affected people tend to overproduce TNF causing inflammatory reactions. Most of these conditions are autoimmune disorders. TNF inhibitors or blockers are anti-inflammatory drugs, designed to stop TNF overproduction.
The TNF inhibitors drugs market is segmented by products. Currently, there are five approved TNF inhibitors: adalimumab, etanercept, infliximab, golimumab, and certolizumab. Although the products continue to generate high commercial sales, patent expirations have driven the emergence of biosimilars. In addition, the impending launch of pipeline candidates is a potent growth driver for this market.
The TNF inhibitors drugs market is further on the basis of applications into the following: rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and hidradenitis suppurativa. Based on sales channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
Some of the major players in the global tumor necrosis factor inhibitor drugs market include AbbVie, Inc.; Amgen, Inc.; Johnson & Johnson Services, Inc.; Novartis International AG; Pfizer, Inc.; and UCB S.A., Samsung Bioepis Co. Ltd., and Boehringer Ingelheim Pharmaceuticals, Inc.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."